MichaelJasonNathensonMD

Oncology • Boston, MA

Hematologic Oncology, Sarcoma

Medical Oncology at Dana-Farber Cancer Institute

Join to view full profile

Dr. Nathenson is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Nathenson's full profile

Already have an account?

Office
450 Brookline Ave
# Dana-Far
Boston, MA 02215
Phone+1 617-582-9396

Education & Training

University of Texas Health Science Center at Houston/M D Anderson Cancer CenterFellowship, Hematology and Medical Oncology, 2015 - 2016
University of MarylandFellowship, Hematology and Medical Oncology, 2012 - 2015
UPMC Medical EducationResidency, Internal Medicine, 2009 - 2012
Tufts University School of MedicineClass of 2009

Certifications & Licensure

MA State Medical License 2016 - 2027
NH State Medical License 2024 - 2024
RI State Medical License 2020 - 2020
TX State Medical License 2015 - 2017
MD State Medical License 2012 - 2015
PA State Medical License 2009 - 2012
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Clinical Trials

A Phase II Study of Eribulin and Pembrolizumab in Soft Tissue Sarcomas Start of enrollment: 2019 May 13
Active, not recruiting
Phase 2

Publications & Presentations

PubMed

Letetresgene Autoleucel in Advanced/Metastatic Myxoid/Round Cell Liposarcoma.
Sandra P D'Angelo, Mihaela Druta, Brian A Van Tine, David Liebner, Scott M Schuetze
Journal of Clinical Oncology. 2025-01-21
6 citations
Phase II Study of Eribulin plus Pembrolizumab in Metastatic Soft-tissue Sarcomas: Clinical Outcomes and Biological Correlates.
Candace L Haddox, Michael J Nathenson, Emanuele Mazzola, Jia-Ren Lin, Joanna Baginska
Clinical Cancer Research. 2024-04-01
14 citations
A global collaboRAtive study of CIC-rearranged, BCOR::CCNB3-rearranged and other ultra-rare unclassified undifferentiated small round cell sarcomas (GRACefUl).
Emanuela Palmerini, Marco Gambarotti, Antoine Italiano, Michael J Nathenson, Ravin Ratan
European Journal of Cancer. 2023-04-01

Lectures

Molecular characterization and management of secondary resistance to serial TRK inhibitors.
2019 ASCO Annual Meeting - 6/1/2019